nodes	percent_of_prediction	percent_of_DWPC	metapath
Tofisopam—CYP3A4—Temozolomide—skin cancer	0.265	0.292	CbGbCtD
Tofisopam—CYP3A4—Imiquimod—skin cancer	0.265	0.292	CbGbCtD
Tofisopam—CYP3A4—Vismodegib—skin cancer	0.184	0.202	CbGbCtD
Tofisopam—CYP3A4—Vemurafenib—skin cancer	0.145	0.16	CbGbCtD
Tofisopam—CYP3A4—Docetaxel—skin cancer	0.0499	0.0548	CbGbCtD
Tofisopam—PDE3A—penis—skin cancer	0.0289	0.339	CbGeAlD
Tofisopam—PDE2A—nipple—skin cancer	0.0132	0.155	CbGeAlD
Tofisopam—PDE2A—mammalian vulva—skin cancer	0.00772	0.0908	CbGeAlD
Tofisopam—PDE2A—female reproductive system—skin cancer	0.00661	0.0777	CbGeAlD
Tofisopam—PDE10A—head—skin cancer	0.00553	0.065	CbGeAlD
Tofisopam—PDE2A—head—skin cancer	0.00553	0.065	CbGeAlD
Tofisopam—PDE10A—lymph node—skin cancer	0.00387	0.0455	CbGeAlD
Tofisopam—PDE2A—lymph node—skin cancer	0.00387	0.0455	CbGeAlD
Tofisopam—PDE3A—female reproductive system—skin cancer	0.00377	0.0443	CbGeAlD
Tofisopam—PDE4A—lymph node—skin cancer	0.00266	0.0313	CbGeAlD
Tofisopam—PDE3A—lymph node—skin cancer	0.0022	0.0259	CbGeAlD
Tofisopam—CYP3A4—female reproductive system—skin cancer	0.00121	0.0142	CbGeAlD
Tofisopam—PDE2A—G alpha (s) signalling events—MC1R—skin cancer	0.000371	0.0771	CbGpPWpGaD
Tofisopam—PDE10A—G alpha (s) signalling events—MC1R—skin cancer	0.000281	0.0584	CbGpPWpGaD
Tofisopam—PDE2A—G alpha (s) signalling events—PTGER4—skin cancer	0.000244	0.0507	CbGpPWpGaD
Tofisopam—PDE10A—G alpha (s) signalling events—PTGER4—skin cancer	0.000185	0.0384	CbGpPWpGaD
Tofisopam—PDE4A—G alpha (s) signalling events—MC1R—skin cancer	0.00017	0.0354	CbGpPWpGaD
Tofisopam—PDE3A—G alpha (s) signalling events—MC1R—skin cancer	0.000166	0.0344	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—RHOU—skin cancer	0.000116	0.024	CbGpPWpGaD
Tofisopam—PDE4A—G alpha (s) signalling events—PTGER4—skin cancer	0.000112	0.0233	CbGpPWpGaD
Tofisopam—PDE3A—G alpha (s) signalling events—PTGER4—skin cancer	0.000109	0.0226	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—PTCH2—skin cancer	9.56e-05	0.0199	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—RHOU—skin cancer	8.77e-05	0.0182	CbGpPWpGaD
Tofisopam—PDE2A—GPCR downstream signaling—MC1R—skin cancer	7.61e-05	0.0158	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—PTCH2—skin cancer	7.25e-05	0.0151	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—MC1R—skin cancer	6.91e-05	0.0144	CbGpPWpGaD
Tofisopam—PDE10A—GPCR downstream signaling—MC1R—skin cancer	5.77e-05	0.012	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—PTCH2—skin cancer	5.65e-05	0.0117	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—RHOU—skin cancer	5.31e-05	0.011	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—MC1R—skin cancer	5.24e-05	0.0109	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—RHOU—skin cancer	5.17e-05	0.0107	CbGpPWpGaD
Tofisopam—PDE2A—GPCR downstream signaling—PTGER4—skin cancer	5.01e-05	0.0104	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—SHH—skin cancer	4.93e-05	0.0102	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—PTCH1—skin cancer	4.67e-05	0.0097	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—SMO—skin cancer	4.67e-05	0.0097	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—PTGER4—skin cancer	4.55e-05	0.00945	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—PTCH2—skin cancer	4.39e-05	0.00912	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—GLI2—skin cancer	4.28e-05	0.0089	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—PTCH2—skin cancer	4.28e-05	0.0089	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—PTCH2—skin cancer	4.27e-05	0.00888	CbGpPWpGaD
Tofisopam—PDE4A—G Protein Signaling Pathways—NRAS—skin cancer	4.14e-05	0.00861	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—MC1R—skin cancer	4.08e-05	0.00849	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—GLI1—skin cancer	4.03e-05	0.00836	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—SUFU—skin cancer	3.82e-05	0.00793	CbGpPWpGaD
Tofisopam—PDE10A—GPCR downstream signaling—PTGER4—skin cancer	3.79e-05	0.00788	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—SHH—skin cancer	3.73e-05	0.00776	CbGpPWpGaD
Tofisopam—PDE4A—G Protein Signaling Pathways—KRAS—skin cancer	3.56e-05	0.00741	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—SMO—skin cancer	3.54e-05	0.00735	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—PTCH1—skin cancer	3.54e-05	0.00735	CbGpPWpGaD
Tofisopam—PDE4A—GPCR downstream signaling—MC1R—skin cancer	3.5e-05	0.00726	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—PTGER4—skin cancer	3.45e-05	0.00716	CbGpPWpGaD
Tofisopam—PDE3A—GPCR downstream signaling—MC1R—skin cancer	3.4e-05	0.00707	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—GLI2—skin cancer	3.24e-05	0.00674	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—MC1R—skin cancer	3.17e-05	0.0066	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—MC1R—skin cancer	3.1e-05	0.00643	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—MC1R—skin cancer	3.09e-05	0.00642	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—GLI1—skin cancer	3.05e-05	0.00634	CbGpPWpGaD
Tofisopam—PDE4A—G Protein Signaling Pathways—HRAS—skin cancer	3.03e-05	0.0063	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—SHH—skin cancer	2.91e-05	0.00605	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—RASA1—skin cancer	2.89e-05	0.00601	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—SUFU—skin cancer	2.89e-05	0.00601	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—PTCH1—skin cancer	2.76e-05	0.00573	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—SMO—skin cancer	2.76e-05	0.00573	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—PTGER4—skin cancer	2.69e-05	0.00558	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—PTCH2—skin cancer	2.59e-05	0.00539	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—PTCH2—skin cancer	2.52e-05	0.00524	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—FOXO4—skin cancer	2.37e-05	0.00493	CbGpPWpGaD
Tofisopam—PDE2A—Hemostasis—NRAS—skin cancer	2.33e-05	0.00483	CbGpPWpGaD
Tofisopam—PDE4A—GPCR downstream signaling—PTGER4—skin cancer	2.3e-05	0.00478	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—SHH—skin cancer	2.26e-05	0.0047	CbGpPWpGaD
Tofisopam—PDE3A—GPCR downstream signaling—PTGER4—skin cancer	2.24e-05	0.00465	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—SHH—skin cancer	2.21e-05	0.00458	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—SHH—skin cancer	2.2e-05	0.00457	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—RASA1—skin cancer	2.19e-05	0.00455	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—PTCH1—skin cancer	2.14e-05	0.00446	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—SMO—skin cancer	2.14e-05	0.00446	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—PTCH1—skin cancer	2.09e-05	0.00434	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—SMO—skin cancer	2.09e-05	0.00434	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—PTGER4—skin cancer	2.09e-05	0.00434	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—PTCH1—skin cancer	2.09e-05	0.00433	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—SMO—skin cancer	2.09e-05	0.00433	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—PTGER4—skin cancer	2.04e-05	0.00423	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—PTGER4—skin cancer	2.03e-05	0.00422	CbGpPWpGaD
Tofisopam—PDE2A—Hemostasis—KRAS—skin cancer	2e-05	0.00416	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—GLI2—skin cancer	1.97e-05	0.00408	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—GLI2—skin cancer	1.91e-05	0.00397	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—MC1R—skin cancer	1.88e-05	0.0039	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—GLI1—skin cancer	1.85e-05	0.00384	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—MC1R—skin cancer	1.82e-05	0.00379	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—GLI1—skin cancer	1.8e-05	0.00374	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—FOXO4—skin cancer	1.8e-05	0.00374	CbGpPWpGaD
Tofisopam—PDE2A—Hemostasis—TP53—skin cancer	1.78e-05	0.0037	CbGpPWpGaD
Tofisopam—PDE10A—Hemostasis—NRAS—skin cancer	1.76e-05	0.00366	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—SUFU—skin cancer	1.75e-05	0.00364	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—SUFU—skin cancer	1.7e-05	0.00354	CbGpPWpGaD
Tofisopam—PDE2A—Hemostasis—HRAS—skin cancer	1.7e-05	0.00354	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—TERT—skin cancer	1.58e-05	0.00329	CbGpPWpGaD
Tofisopam—PDE10A—Hemostasis—KRAS—skin cancer	1.52e-05	0.00315	CbGpPWpGaD
Tofisopam—PDE10A—Hemostasis—TP53—skin cancer	1.35e-05	0.0028	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—SHH—skin cancer	1.34e-05	0.00278	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—NRAS—skin cancer	1.34e-05	0.00277	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—RASA1—skin cancer	1.33e-05	0.00276	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—SHH—skin cancer	1.3e-05	0.0027	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—RASA1—skin cancer	1.29e-05	0.00268	CbGpPWpGaD
Tofisopam—PDE10A—Hemostasis—HRAS—skin cancer	1.29e-05	0.00268	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—SMO—skin cancer	1.27e-05	0.00263	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—PTCH1—skin cancer	1.27e-05	0.00263	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—BRAF—skin cancer	1.26e-05	0.00261	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—PTGER4—skin cancer	1.23e-05	0.00256	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—PTCH1—skin cancer	1.23e-05	0.00256	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—SMO—skin cancer	1.23e-05	0.00256	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—TERT—skin cancer	1.2e-05	0.0025	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—PTGER4—skin cancer	1.2e-05	0.00249	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—KRAS—skin cancer	1.15e-05	0.00239	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—FOXO4—skin cancer	1.09e-05	0.00226	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—FOXO4—skin cancer	1.06e-05	0.0022	CbGpPWpGaD
Tofisopam—PDE3A—Hemostasis—NRAS—skin cancer	1.04e-05	0.00216	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—NRAS—skin cancer	1.01e-05	0.0021	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—HRAS—skin cancer	9.77e-06	0.00203	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—BRAF—skin cancer	9.51e-06	0.00198	CbGpPWpGaD
Tofisopam—PDE2A—Signaling by GPCR—IL6—skin cancer	9.35e-06	0.00194	CbGpPWpGaD
Tofisopam—PDE3A—Hemostasis—KRAS—skin cancer	8.94e-06	0.00186	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—KRAS—skin cancer	8.71e-06	0.00181	CbGpPWpGaD
Tofisopam—PDE3A—Hemostasis—TP53—skin cancer	7.95e-06	0.00165	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—NRAS—skin cancer	7.89e-06	0.00164	CbGpPWpGaD
Tofisopam—PDE3A—Hemostasis—HRAS—skin cancer	7.6e-06	0.00158	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—HRAS—skin cancer	7.4e-06	0.00154	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—TERT—skin cancer	7.28e-06	0.00151	CbGpPWpGaD
Tofisopam—PDE10A—Signaling by GPCR—IL6—skin cancer	7.09e-06	0.00147	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—TERT—skin cancer	7.08e-06	0.00147	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—KRAS—skin cancer	6.79e-06	0.00141	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—NRAS—skin cancer	6.13e-06	0.00127	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—TP53—skin cancer	6.03e-06	0.00125	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—NRAS—skin cancer	5.98e-06	0.00124	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—NRAS—skin cancer	5.96e-06	0.00124	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—HRAS—skin cancer	5.77e-06	0.0012	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—BRAF—skin cancer	5.76e-06	0.0012	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—BRAF—skin cancer	5.61e-06	0.00116	CbGpPWpGaD
Tofisopam—PDE2A—Signaling Pathways—IL6—skin cancer	5.52e-06	0.00115	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—KRAS—skin cancer	5.28e-06	0.0011	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—KRAS—skin cancer	5.14e-06	0.00107	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—KRAS—skin cancer	5.13e-06	0.00107	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—TP53—skin cancer	4.57e-06	0.00095	CbGpPWpGaD
Tofisopam—CYP3A4—Metabolism—PLIN2—skin cancer	4.52e-06	0.000939	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—HRAS—skin cancer	4.48e-06	0.000932	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—HRAS—skin cancer	4.37e-06	0.000909	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—HRAS—skin cancer	4.36e-06	0.000906	CbGpPWpGaD
Tofisopam—PDE4A—Signaling by GPCR—IL6—skin cancer	4.29e-06	0.000892	CbGpPWpGaD
Tofisopam—PDE10A—Signaling Pathways—IL6—skin cancer	4.19e-06	0.00087	CbGpPWpGaD
Tofisopam—PDE3A—Signaling by GPCR—IL6—skin cancer	4.18e-06	0.000868	CbGpPWpGaD
Tofisopam—CYP3A4—Metabolism—CSPG4—skin cancer	3.64e-06	0.000756	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—NRAS—skin cancer	3.62e-06	0.000752	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—NRAS—skin cancer	3.52e-06	0.000732	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—KRAS—skin cancer	3.12e-06	0.000648	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—KRAS—skin cancer	3.03e-06	0.00063	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—TP53—skin cancer	2.77e-06	0.000576	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—TP53—skin cancer	2.69e-06	0.00056	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—HRAS—skin cancer	2.65e-06	0.00055	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—HRAS—skin cancer	2.58e-06	0.000535	CbGpPWpGaD
Tofisopam—PDE4A—Signaling Pathways—IL6—skin cancer	2.54e-06	0.000527	CbGpPWpGaD
Tofisopam—CYP3A4—Metabolism—ENO2—skin cancer	2.48e-06	0.000514	CbGpPWpGaD
Tofisopam—PDE3A—Signaling Pathways—IL6—skin cancer	2.47e-06	0.000513	CbGpPWpGaD
Tofisopam—CYP3A4—Metabolism—ERCC2—skin cancer	1.44e-06	0.000299	CbGpPWpGaD
Tofisopam—CYP3A4—Metabolism—PTGS2—skin cancer	8.62e-07	0.000179	CbGpPWpGaD
